



THE  
BLADDER CANCER  
COMPANY

# Photocure appoints Anders Neijber as Vice President, Global Medical Affairs and Clinical Development

**Press Release – Oslo, Norway, September 1, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Anders Neijber as Vice President, Global Medical Affairs and Clinical Development, effective September 1st, 2021.**

Mr. Neijber brings over 25 years of substantial experience in the uro-oncology area and successful leadership in the pharmaceutical industry. He has had global and regional assignments, both in the U.S. and Europe, within Clinical R&D and Medical Affairs, having worked for Pfizer, AstraZeneca, Johnson&Johnson, Allergan and Ferring, where he held a similar global Medical Affairs leadership role as V.P., Global Therapeutic Area Head Uro-Oncology. Most recently he led Medical Affairs for Novartis in the Nordics.

Anders completed his MD and PhD from Karolinska University, is a board-certified urologist, and also holds an MBA from Western Michigan University. He held an assistant Professor position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical School, New Jersey.

In his new position, Anders Neijber will be a member of the Photocure Executive Leadership Team.

*"I am very pleased to welcome Anders Neijber to the Management Team of Photocure. I look forward to his leadership leveraging his deep knowledge in the field of Urology and experience in leading a Global Medical Affairs strategy. I believe having Anders in this strategic position will help us achieve our vision of leading change in bladder cancer."* says Dan Schneider, President and Chief Executive Officer of Photocure.

## **Note to editors:**

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA

## **About Photocure ASA**

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the

Oslo Stock Exchange (OSE: PHO). For more information, please visit us at [www.photocure.com](http://www.photocure.com),  
[www.hexvix.com](http://www.hexvix.com), [www.cysview.com](http://www.cysview.com)

**For further information, please contact:**

Dan Schneider  
President and CEO  
Photocure ASA  
Email: [ds@photocure.com](mailto:ds@photocure.com)

Erik Dahl  
CFO  
Photocure ASA  
Tel: +4745055000  
Email: [ed@photocure.com](mailto:ed@photocure.com)

David Moskowitz  
Head of Investor Relations  
Tel: +1 202 280 0888  
Email: [david.moskowitz@photocure.com](mailto:david.moskowitz@photocure.com)

Media and IR enquiries:

Geir Bjørlo  
Corporate Communications (Norway)  
Tel: +47 91540000  
Email: [geir.bjorlo@corpcom.no](mailto:geir.bjorlo@corpcom.no)